Physician profile
Michael B Auerbach
NPI 1306157201
$12,450.28
in general payments reported to CMS, 2019-2025
32 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $97.67 · 2021: $2,290 · 2022: $4,293 · 2023: $3,872 · 2024: $1,079 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940 · Consulting Fee: $2,000 · Travel and Lodging: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.23 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $699.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $3,352.99 | 2022-2023 | Reactiv8 |
| Si-Bone, INC. | $2,000.00 | 2023 | |
| Spinal Simplicity, LLC | $1,897.33 | 2021-2024 | Ha Minuteman G3-R |
| Nevro Corp. | $882.30 | 2020-2024 | Senza |
| Boston Scientific Corporation | $795.68 | 2021-2024 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Vertos Medical, INC. | $685.86 | 2022-2024 | Mild Device Kit |
| Spr Therapeutics, INC | $413.12 | 2020-2025 | Sprint Pns System |
| Globus Medical, INC. | $400.35 | 2025 | Senza, Vyrsa V1 |
| Collegium Pharmaceutical, INC. | $319.56 | 2022-2025 | Belbuca |
| Captiva Spine INC | $301.39 | 2023 | Caplox Ll |
| Tersera Therapeutics LLC | $224.29 | 2023-2025 | Prialt |
| Depuy Synthes Sales INC. | $174.03 | 2021-2024 | Monovisc, Orthovisc |
| Abbott Laboratories | $159.34 | 2022-2025 | Eterna, Proclaim |
| Biodelivery Sciences International, INC. | $134.62 | 2021 | |
| Medtronic, INC. | $102.67 | 2021-2023 | Intellis Adaptivestim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $88.18 | 2024-2025 | Prospera |
| Southern Edge Orthopaedics, INC. | $80.87 | 2024 | |
| Forte Bio-Pharma LLC | $59.92 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $45.00 | 2023-2025 | Exparel, Zilretta, Iovera |
| Gilead Sciences, INC. | $43.56 | 2023-2025 | Trodelvy |
| Kowa Pharmaceuticals America, INC. | $37.41 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $30.66 | 2025 | |
| Stimwave Technologies Incorporated | $30.25 | 2019 | |
| Nalu Medical, INC. | $28.12 | 2025 | Nalu Neurostimulation System |
| Pfizer INC. | $27.07 | 2024 | |
| Grt US Holding, INC. | $24.52 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.81 | 2023 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $20.79 | 2019 | |
| West Therapeutics Development, LLC | $20.68 | 2021 | |
| Interventional Pain Technologies INC. | $20.41 | 2022 | |
| Seagen INC. | $17.90 | 2019 | |
| Augmedics INC. | $10.60 | 2025 | Xvision |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Auerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.